health canada approval zepbound tirzepatide obesity canada 2024 2025 ZEPBOUND™ KWIKPEN® (TIRZEPATIDE INJECTION), THE FIRST AND ONLY DUAL RECEPTOR AGONIST FOR THE TREATMENT OF OBESITY, NOW APPROVED AND AVAILABLE IN New Zepbound TV Commercial Inspires

Specialized in Oncology Products

Claya separates a low membership fee from the medication bill, so your true number is the combined monthly total at your steady (maintenance) dose

Zepbound was approved a year and a half later, in November 2023, for chronic weight management in adults with obesity as well as those who are overweight and have at least one weight-related condition (like high blood pressure or high cholesterol)

There were cases of MTC reported in patients who took liraglutide (the active ingredient in Ozempic and Wegovy) after the drug was put on the market

Do your partnered dispensaries source medications internationally